News | January 02, 2025
Innovent inks agreement with Roche for Novel DLL3 ADC
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins
Merck has also decided to end the favezelimab clinical development program
Venus Remedies secures marketing authorization in Philippines
WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
Subscribe To Our Newsletter & Stay Updated
